مواقع ذات صلة
الخط الساخن للخدمات الصحية للنازحين اللبنانيين 1787   
الخط الساخن لدخول المرضى الى المستشفيات 01/832700   
التسجيل لأخذ لقاح الكورونا covax.moph.gov.lb   
الخط الساخن لوزارة الصحّة العامة 1214   
هل أنت مستخدم جديد؟ قم بالتسجيل الآن
 
دعنا نساعدك
للوصول إلى هدفك.

لمحة عامة

 
Health care that is driven by quality across a range of services within the hospital system is attractive and marketable to other countries. The image of hospitals as upmarket hotels can be transported but only through the application of consistent, safe and considerate patient care. Establishment of a hospital accreditation system in Lebanon, once fully implemented will pave the way for the provision of good quality of health care. As the accreditation system matures the standards will further develop and quality assurance and quality improvement will lead on to the more precise measurement of health outcomes.

A broad range of quality measures will be discussed in this paper to show that when the ethic of quality is embedded within the health system, the delivery, utilisation and growth of acute hospital services in Lebanon is more attractive to local patients and neighboring countries. It is vital that the concepts of quality assurance and quality improvement be seen as critical and not as an adjunct to hotel services, and quality and accommodation standards are not viewed in isolation. The development of quality hotel services is linked quite clearly to quality generally, whether it is in the building/infrastructural component, the furbishing component, equipment or the patient care services.

Quality assurance principles and hospital accreditation address quality of care deficiencies and harmful and/or wasteful practices, and can stimulate debate between public and private providers, policy makers and consumers on what practices conform to the latest reliable evidence. This promotes a wider dissemination of knowledge. Increased knowledge and awareness by the public ensures that hospitals achieve greater throughputs because of the public's faith that the hospital is able to meet the wide range of quality standards.

Hospital management have often remarked during visits of the OPCV Survey Team that unless a hospital provided "the full options"- that is a complete range of the latest sophisticated medical technology - then it was not considered to be a good hospital. Scant attention is paid to whether the size and complexity of the hospital warrants a complete range of equipment, or indeed whether the hospital can provide the qualified staff necessary to operate such equipment safely. The image of what constitutes a good hospital is generally supported by the current Hospital Classification system and it this image that is required to be changed through the implementation of quality assurance/improvement to support the marketing of Lebanon's hospital services to other countries. A public education campaign is therefore a concomitant exercise to be carried out in parallel with the development of the quality approach .
    ...
    12
    ...
التصنيف العلاجي الاسم أساسي / جنيسي التركيبة العلمية العيار الشكل الصيدلاني سعر المبيع من العموم
L01BC01 ALEXAN G Cytarabine - 100mg/5ml 100mg/5ml Injectable solution 388,370 L.L
L01BC01 ALEXAN G Cytarabine - 1,000mg/20ml 1,000mg/20ml Injectable solution 2,848,946 L.L
L01BC07 AZACITIDINE ARROW G Azacitidine - 25mg/ml 25mg/ml Injectable suspension 10,967,854 L.L
L01BC07 AZACITIDINE EVER PHARMA G Azacitidine - 100mg/100ml 25mg/ml Injectable powder for suspension 10,967,854 L.L
L01BC07 AZACITIDINE NEAPOLIS G Azacitidine - 100mg 100mg Injectable lyophilised powder 9,401,575 L.L
L01BC07 AZACITIDINE SPC G Azacitidine - 100mg 100mg Injectable powder 10,706,993 L.L
L01CD01 ABRAXANE BioTech Paclitaxel Albumin- bound - 5mg/ml 5mg/ml Injectable powder for dispersion 17,850,751 L.L
L01EA01 APO-IMATINIB G Imatinib - 100mg 100mg Tablet 18,838,684 L.L
L01EA02 APO-DASATINIB G Dasatinib - 70mg 70mg Tablet 71,323,688 L.L
L01EA02 APO-DASATINIB G Dasatinib - 50mg 50mg Tablet 71,323,688 L.L
L01EA02 APO-DASATINIB G Dasatinib - 20mg 20mg Tablet 57,771,855 L.L
L01EB01 APO-GEFITINIB G Gefitinib - 250mg 250mg Tablet 87,345,820 L.L
L01EB02 APO-ERLOTINIB G Erlotinib (HCl) - 100mg 100mg Tablet 79,672,726 L.L
L01EB02 APO-ERLOTINIB G Erlotinib (HCl) - 150mg 150mg Tablet 91,523,229 L.L
L01ED03 ALECENSA B Alectinib - 150mg 150mg Capsule, hard 490,837,809 L.L
L01ED03 ALECENSA B Alectinib - 150mg 150mg Capsule, hard L.L
L01ED04 ALUNBRIG B Brigatinib - 30mg 30mg Tablet, film coated 124,685,776 L.L
L01ED04 ALUNBRIG B Brigatinib - 90mg 90mg Tablet, film coated 374,059,747 L.L
L01ED04 ALUNBRIG B Brigatinib - 180mg 180mg Tablet, film coated 493,595,998 L.L
L01EG02 AFINITOR B Everolimus - 5mg 5mg Tablet 149,280,650 L.L
L01EG02 AFINITOR B Everolimus - 10mg 10mg Tablet 214,897,705 L.L
L01FD01 ARYOTRUST BioTech Trastuzumab - 440mg 440mg Injectable powder for concentrate for solution + solvent 34,948,930 L.L
L01FD01 ARYOTRUST BioTech Trastuzumab - 150mg 150mg Injectable powder for concentrate for solution 21,176,745 L.L
L01FG01 AVASTIN BioTech Bevacizumab - 400mg/16ml 400mg/16ml Injectable concentrated solution 75,875,312 L.L
L01FG01 AVASTIN BioTech Bevacizumab - 400mg 400mg Injectable concentrated solution 75,875,312 L.L
L01FG01 AVASTIN BioTech Bevacizumab - 100mg/4ml 100mg/4ml Injectable concentrated solution 24,533,456 L.L
L01FG01 AVASTIN BioTech Bevacizumab - 100mg 100mg Injectable concentrated solution 24,533,456 L.L
L01FX05 ADCETRIS BioTech Brentuximab Vedotin - 50mg 50mg Injectable powder for concentrate for solution L.L
L01FX05 ADCETRIS BioTech Brentuximab Vedotin - 50mg 50mg Injectable powder for concentrate for solution 298,266,862 L.L
L01XG01 ALVOCADE G Bortezomib - 3.5mg 3.5mg Injectable powder for solution 14,169,600 L.L
    ...
    12
    ...
Sitemap
حقوق الطبع والنشر محفوظة ل وزارة الصحة العامة ©2025